Mathematical modeling identifies optimum lapatinib dosing schedules for the treatment of glioblastoma patients
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Mathematical modeling identifies optimum lapatinib dosing schedules for the treatment of glioblastoma patients
Authors
Keywords
Cancer treatment, Toxicity, Drug therapy, Cell motility, Blood-brain barrier, Death rates, Dose prediction methods, Pharmacokinetics
Journal
PLoS Computational Biology
Volume 14, Issue 1, Pages e1005924
Publisher
Public Library of Science (PLoS)
Online
2018-01-03
DOI
10.1371/journal.pcbi.1005924
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The biology and mathematical modelling of glioma invasion: a review
- (2017) J. C. L. Alfonso et al. Journal of the Royal Society Interface
- Intra-tumor heterogeneity from a cancer stem cell perspective
- (2017) Pramudita R. Prasetyanti et al. Molecular Cancer
- Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients withEGFR-mutant lung cancers
- (2016) H. A. Yu et al. ANNALS OF ONCOLOGY
- Understanding Intratumoral Heterogeneity: Lessons from the Analysis of At-Risk Tissue and Premalignant Lesions in the Colon
- (2016) C. K. Sievers et al. Cancer Prevention Research
- Pharmacodynamic modeling of adverse effects of anti-cancer drug treatment
- (2016) A. H. M. de Vries Schultink et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Glioblastoma, hypoxia and autophagy: a survival-prone ‘ménage-à-trois’
- (2016) Soha Jawhari et al. Cell Death & Disease
- Glioblastoma multiforme: Effect of hypoxia and hypoxia inducible factors on therapeutic approaches
- (2016) Wen-Juan Huang et al. Oncology Letters
- Strategies of Mesenchymal Invasion of Patient-derived Brain Tumors: Microenvironmental Adaptation
- (2016) Junghwa Cha et al. Scientific Reports
- A Modeling and Simulation Framework for Adverse Events in Erlotinib-Treated Non-Small-Cell Lung Cancer Patients
- (2015) Ahmed Abbas Suleiman et al. AAPS Journal
- Patient-Specific Mathematical Neuro-Oncology: Using a Simple Proliferation and Invasion Tumor Model to Inform Clinical Practice
- (2015) Pamela R. Jackson et al. BULLETIN OF MATHEMATICAL BIOLOGY
- Hypoxia enhances migration and invasion in glioblastoma by promoting a mesenchymal shift mediated by the HIF1α–ZEB1 axis
- (2015) Justin V. Joseph et al. CANCER LETTERS
- The Evidence of Glioblastoma Heterogeneity
- (2015) Akio Soeda et al. Scientific Reports
- Targeting adaptive glioblastoma: an overview of proliferation and invasion
- (2014) Q. Xie et al. NEURO-ONCOLOGY
- Intratumor heterogeneity: Nature and biological significance
- (2013) T. S. Gerashchenko et al. BIOCHEMISTRY-MOSCOW
- Cancer heterogeneity: implications for targeted therapeutics
- (2013) R Fisher et al. BRITISH JOURNAL OF CANCER
- A Phase I/II Trial of Pazopanib in Combination with Lapatinib in Adult Patients with Relapsed Malignant Glioma
- (2013) D. A. Reardon et al. CLINICAL CANCER RESEARCH
- Tumour heterogeneity
- (2013) Barbara Marte NATURE
- The causes and consequences of genetic heterogeneity in cancer evolution
- (2013) Rebecca A. Burrell et al. NATURE
- Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
- (2013) Meghna Das Thakur et al. NATURE
- From Patient-Specific Mathematical Neuro-Oncology to Precision Medicine
- (2013) A. L. Baldock et al. Frontiers in Oncology
- Novel Delivery Strategies for Glioblastoma
- (2012) Jiangbing Zhou et al. CANCER JOURNAL
- Intratumor Heterogeneity: Evolution through Space and Time
- (2012) C. Swanton CANCER RESEARCH
- A Phase II Study of Lapatinib in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
- (2012) J. A. de Souza et al. CLINICAL CANCER RESEARCH
- Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer
- (2012) Kimberly K. Leslie et al. GYNECOLOGIC ONCOLOGY
- Expected Benefits of Topotecan Combined With Lapatinib in Recurrent Ovarian Cancer According to Biological Profile
- (2012) Stéphanie Lheureux et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
- (2012) Marco Gerlinger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Differential Sensitivity of Glioma- versus Lung Cancer–Specific EGFR Mutations to EGFR Kinase Inhibitors
- (2012) Igor Vivanco et al. Cancer Discovery
- The Impact of Phenotypic Switching on Glioblastoma Growth and Invasion
- (2012) Philip Gerlee et al. PLoS Computational Biology
- Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck
- (2011) J M del Campo et al. BRITISH JOURNAL OF CANCER
- The brain tumor microenvironment
- (2011) Nikki A. Charles et al. GLIA
- A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A gynecologic oncology group study
- (2011) Agustin A. Garcia et al. GYNECOLOGIC ONCOLOGY
- "Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer
- (2011) C. Grommes et al. NEURO-ONCOLOGY
- Optimization of Dosing for EGFR-Mutant Non-Small Cell Lung Cancer with Evolutionary Cancer Modeling
- (2011) J. Chmielecki et al. Science Translational Medicine
- A Multicenter Phase II Clinical Trial of Lapatinib (GW572016) in Hormonally Untreated Advanced Prostate Cancer
- (2010) Srikala S. Sridhar et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- The Origins and Implications of Intratumor Heterogeneity
- (2010) F. Michor et al. Cancer Prevention Research
- A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080
- (2010) Ron J. Keizer et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- 'Go or Grow': the key to the emergence of invasion in tumour progression?
- (2010) H. Hatzikirou et al. MATHEMATICAL MEDICINE AND BIOLOGY-A JOURNAL OF THE IMA
- Modeling the Cancer Stem Cell Hypothesis
- (2010) C. Calmelet et al. Mathematical Modelling of Natural Phenomena
- A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation
- (2009) Brian Thiessen et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer
- (2009) Ramesh K. Ramanathan et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A Phase I and Pharmacokinetic Study of Oral Lapatinib Administered Once or Twice Daily in Patients with Solid Malignancies
- (2009) H. A. Burris et al. CLINICAL CANCER RESEARCH
- A Phase I Study of a 2-Day Lapatinib Chemosensitization Pulse Preceding Nanoparticle Albumin-Bound Paclitaxel for Advanced Solid Malignancies
- (2009) A. J. Chien et al. CLINICAL CANCER RESEARCH
- A Multi-Institutional Phase II Study of the Efficacy and Tolerability of Lapatinib in Patients with Advanced Hepatocellular Carcinomas
- (2009) T. Bekaii-Saab et al. CLINICAL CANCER RESEARCH
- PDGF stimulates the massive expansion of glial progenitors in the neonatal forebrain
- (2009) M. C. Assanah et al. GLIA
- Pharmacodynamics of 2- ethan-1-ol (GDC-0879), a Potent and Selective B-Raf Kinase Inhibitor: Understanding Relationships between Systemic Concentrations, Phosphorylated Mitogen-Activated Protein Kinase Kinase 1 Inhibition, and Efficacy
- (2009) H. Wong et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Lapatinib: A dual tyrosine kinase inhibitor for metastatic breast cancer
- (2008) B. Paul et al. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- Pharmacokinetic-Pharmacodynamic Modeling of Biomarker Response and Tumor Growth Inhibition to an Orally Available cMet Kinase Inhibitor in Human Tumor Xenograft Mouse Models
- (2008) S. Yamazaki et al. DRUG METABOLISM AND DISPOSITION
- Lapatinib Versus Hormone Therapy in Patients With Advanced Renal Cell Carcinoma: A Randomized Phase III Clinical Trial
- (2008) Alain Ravaud et al. JOURNAL OF CLINICAL ONCOLOGY
- Intermittent Target Inhibition With Dasatinib 100 mg Once Daily Preserves Efficacy and Improves Tolerability in Imatinib-Resistant and -Intolerant Chronic-Phase Chronic Myeloid Leukemia
- (2008) Neil P. Shah et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Imatinib in Patients With Recurrent Gliomas of Various Histologies: A European Organisation for Research and Treatment of Cancer Brain Tumor Group Study
- (2008) Eric Raymond et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I/II Trial of Erlotinib and Temozolomide With Radiation Therapy in the Treatment of Newly Diagnosed Glioblastoma Multiforme: North Central Cancer Treatment Group Study N0177
- (2008) Paul D. Brown et al. JOURNAL OF CLINICAL ONCOLOGY
- Malignant Gliomas in Adults
- (2008) Patrick Y. Wen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-β kinase antagonist, in mice
- (2007) Lorea Bueno et al. EUROPEAN JOURNAL OF CANCER
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now